Efficacy and Safety of JAK Inhibitors in Systemic Sclerosis-associated Interstitial Lung Disease
NCT05177471
·
clinicaltrials.gov ↗
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
no eligible patients
Conditions
Systemic Sclerosis
Interstitial Lung Disease
Sponsor
Central Hospital, Nancy, France